Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis
Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Reduvo not approved , will compete with Nabilone (teva drug)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(58)
•••
Post by SamV21on Oct 27, 2021 3:16pm
120 Views
Post# 34055832

Reduvo not approved , will compete with Nabilone (teva drug)

Reduvo not approved , will compete with Nabilone (teva drug)Reduvo does not have approval and it could be June 2022 min. or May 2023 max. , no one has ever told us what it will cost to produce, is it competitive with Nabilone that has been around since 2006 ?You can be sure the system will lean towards what ever is cheaper.Qixleef has applied to be an orphan drug meaning it falls into a low demand drug ( no profit in most cases , look it up) they still have to go through all the phases to be brought to market.If you are going to pump information maybe expand on it and give it realistic time times , don't pump like it any of this will happen any time soon .Pump and dump beware ! 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities